Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
This dynamic can trouble even the most skilled investors, but luckily for you, we started StockStory to help you navigate these trade-offs and uncover exceptional companies that break the mold. Keeping that in mind, here are three large-cap stocks that still have big upside potential.
Snowflake (SNOW)
Market Cap: $54.37 billion
Named after the unique architecture of its data warehouse which resembles a snowflake pattern, Snowflake (NYSE: SNOW) provides a cloud-based data platform that enables organizations to consolidate, analyze, and share data across multiple cloud providers.
Why Should You Buy SNOW?
- Average billings growth of 36% over the last year enhances its liquidity and shows there is steady demand for its products
- Platform plays a pivotal role in customer workflows as its net revenue retention rate punches in at 125%
- Notable projected revenue growth of 26.3% for the next 12 months hints at market share gains
Snowflake’s stock price of $157.80 implies a valuation ratio of 8.7x forward price-to-sales. Is now a good time to buy? Find out in our full research report, it’s free.
EMCOR (EME)
Market Cap: $40.58 billion
Through its network of over 70 subsidiaries, EMCOR (NYSE: EME) provides electrical, mechanical, and building construction and services
Why Is EME a Good Business?
- Market share has increased this cycle as its 16.3% annual revenue growth over the last two years was exceptional
- Share repurchases have amplified shareholder returns as its annual earnings per share growth of 40.2% exceeded its revenue gains over the last two years
- Returns on capital are growing as management capitalizes on its market opportunities
EMCOR is trading at $911.23 per share, or 31.4x forward P/E. Is now the time to initiate a position? See for yourself in our comprehensive research report, it’s free.
Amgen (AMGN)
Market Cap: $176.1 billion
Founded in 1980 during the early days of the biotechnology revolution, Amgen (NASDAQ: AMGN) is a biotechnology company that discovers, develops, and manufactures innovative medicines to treat serious illnesses like cancer, osteoporosis, and autoimmune diseases.
Why Does AMGN Stand Out?
- Annual revenue growth of 12.3% over the last two years beat the sector average and underscores the unique value of its offerings
- Revenue base of $37.22 billion gives it economies of scale and some negotiating power
- Robust free cash flow margin of 27.7% gives it many options for capital deployment
At $325.90 per share, Amgen trades at 4.8x forward price-to-sales. Is now a good time to buy? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
